brimapitide

Ligand id: 9101

Name: brimapitide

Classification
Compound class Peptide or derivative
International Nonproprietary Names
INN number INN
10207 brimapitide
Synonyms
AM-111 | D-JNKI-1 | XG-102
Database Links
Search PubMed clinical trials brimapitide
Search PubMed titles brimapitide
Search PubMed titles/abstracts brimapitide
Comments
Brimapitide is a highly selective, non-competitive, long-acting inhibitor of c-jun N-terminal kinase (JNK). The peptide is an investigational drug for the intratympanic (i.t.) treatment of acute sensorineural hearing loss (ASNHL). Structurally the peptide consists of 20 amino acids from C-Jun-amino-terminal kinase-interacting protein 1 (JIP-1) fused to a carrier peptide derived from HIV-TAT48-57 (TAT) peptide PPRRRQRRKKRG. The peptide is constructed in a D-retro-inverso configuration to render it protease resistant. The TAT peptide mediates cell permeability. The sequence is claimed in patent US8080517 (SEQ ID NO: 11, D-JNKI1) [2]. The research codes XG-102 and AM-111 seem to be applied to this investigational agent.